Answers are grounded in this paper and cite their sources.
Bladder pain syndrome/interstitial cystitis (BPS/IC) is a chronic and debilitating condition characterized by pelvic pain and urinary symptoms in the absence of identifiable pathogens via standard methods. As a heterogeneous syndrome, BPS/IC comprises different clinical phenotypes with distinct underlying pathophysiological mechanisms. This narrative review summarizes the current evidence regarding potential infection-associated phenotypes of BPS/IC and examines urinary microbiome alterations, intracellular bacterial reservoirs, host immune responses, and emerging diagnostic approaches to understand possible infection-associated mechanisms in a subset of patients with BPS/IC. A comprehensive literature review was conducted, focusing on studies related to the urinary microbiome, bacterial survival mechanisms, inflammatory biomarkers, and advanced diagnostic techniques beyond conventional urine culture. Alterations in the urinary microbial composition have been reported in subsets of patients with BPS/IC. Experimental and clinical evidence suggests that certain uropathogens invade urothelial cells and evade host immune responses and antimicrobial treatment. These mechanisms may contribute to the persistent symptoms and culture-negative presentations in a subset of patients with BPS/IC. Advanced diagnostic approaches may improve the detection of specific clinical phenotypes that cannot be identified using conventional diagnostic strategies. Further studies are needed to define these phenotypes and clarify their diagnostic and therapeutic implications. Although current evidence does not support routine antimicrobial treatment for BPS/IC, patients with findings suggestive of infection-associated mechanisms may warrant further evaluation of targeted antimicrobial approaches in future clinical studies. A better understanding of the role of occult bacterial persistence may facilitate the optimization of patient selection, antimicrobial treatment strategies, and duration, potentially supporting targeted approaches as important components of personalized, etiology-directed management in patients within these phenotypic subgroups, with the potential to improve quality of life.
No takes yet. Share an insight, caveat, or question.
Sarkadi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: